CEO SUMMARY: Currently, there are hospital, health system, and independent clinical laboratories that have between two and five different PCR testing platforms. These analyzers were acquired during the pandemic as one way to increase the daily number of SARS-CoV-2 their labs could perform. Today, with the demand for COVID-19 PCR tests dropping steadily, these same […]
Post-COVID: Repurposing Excess PCR Instruments
Question confronting many labs today: What to do with multiple automated PCR instruments?
- By Robert Michel
- > From the Volume XXVIII, No. 15 - November 8, 2021 Issue
- Tags: Abbott Alinity, Abbott ID NOW, AMP, association for molecular pathology, COVID-19 PCR test, DiaSorin Molecular, EUA, FDA, FDA Emergency Use Authorization (EUA), FDA-cleared alternative, FDA-cleared assay, in vitro diagnostics, IVD, IVD Logix, ivd/lab informatics, laboratory-developed tests, Lawrence Worden, ldt, molecular testing, PCR testing platforms, portable rapid molecular test, Post-COVID, Roche cobas 6800, SARS-CoV-2, U.S. Food and Drug Administration
